BC
CLRB icon

Boxer Capital’s Cellectar Biosciences CLRB Stock Holding History

Boxer Capital’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,067
Closed -$851K – 74
2021
Q3 		$851K Hold
3,067
– – 0.03% 86
2021
Q2 		$1.09M Hold
3,067
– – 0.04% 92
2021
Q1 		$1.48M Hold
3,067
– – 0.05% 83
2020
Q4 		$1.91M Hold
3,067
– – 0.06% 76
2020
Q3 		$1.14M Hold
3,067
– – 0.04% 74
2020
Q2 		$1.18M Hold
3,067
– – 0.05% 64
2020
Q1 		$1.23M Hold
3,067
– – 0.08% 60
2019
Q4 		$2.07M Hold
3,067
– – 0.12% 51
2019
Q3 		$1.84M Hold
3,067
– – 0.13% 47
2019
Q2 		$2.01M Buy
+3,067
New +$2.09M 0.17% 36

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital's CLRB Position: Q4 2021 in Review

Boxer Capital sold out of Cellectar Biosciences (CLRB) in Q4 2021, closing a stake of 3,067 shares — an estimated $851K sold.

Boxer Capital first reported a position in CLRB in Q2 2019 and held it in 10 quarters. The position peaked at $2.07M in Q4 2019. 41 funds tracked by Wall St. Rank hold CLRB as of Q4 2021.

  • Boxer Capital reported no remaining Cellectar Biosciences position as of Q4 2021 after selling out during the quarter.
  • Boxer Capital sold 3,067 Cellectar Biosciences shares in Q4 2021, an estimated $851K.
  • Boxer Capital first reported a position in Cellectar Biosciences in Q2 2019 and held it in 10 quarters.
  • Boxer Capital's Cellectar Biosciences position peaked at $2.07M in Q4 2019.
  • 41 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.